Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) CEO David Regan talked with Proactive's Stephen Gunnion about first-in-human data for the company’s targeted hyperthermia therapy (THT), showing significant tumor response in patients with late-stage melanoma. The early feasibility study involved ten patients who had not responded to standard immunotherapy. Regan said, “We were able to get a response in eight out of ten of them, of which six were complete responses.” Biopsies conducted within two weeks confirmed that the treated tumors no longer contained melanoma cells. THT uses nanoparticles injected into tumors and activated by a near-infrared laser. The laser energy creates heat at 45°C, selectively killing cancer cells without harming healthy tissue. The process also stimulates the immune system, which Regan said was a critical component: “We’re really helping to fire up the immune system to fight the cancer on its own.” Sona now plans to move into a Canadian clinical trial, pending Health Canada approval. Regan emphasized that these results could extend beyond melanoma, potentially benefiting other solid tumors resistant to immunotherapy. Investors can expect updates on histological data analysis and direction for broader clinical applications. Sona has already submitted an application to Health Canada and hopes to engage with the regulator soon. #SonaNanotech #CancerTreatment #TargetedHyperthermia #Melanoma #BiotechNews #Immunotherapy #ClinicalTrials #Oncology #MedicalInnovation #HealthcareTech